BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Change in Receivables of -$17000.0 in Q1 2026, down 107.3% quarter-over-quarter from $233000.0 in Q4 2025, and up 87.02% on a YoY basis from -$9089.8 in Q1 2025.
BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2026) Analysis & Trends
BioXcel Therapeutics' Change in Receivables history runs 4 years deep, the most recent figure standing at -$17000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 87.02% year-over-year to -$17000.0; the TTM figure through Mar 2026 stood at $216000.0 (up 157.14% YoY), while the FY2025 annual figure was $102000.0, up 70.0% from the prior year.
- Change in Receivables was -$17000.0 for Q1 2026 at BioXcel Therapeutics, down from $233000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $434000.0 in Q2 2024 to a low of -$809000.0 in Q3 2024.
- Historically, Change in Receivables has averaged -$2461.5 across 4 years, with a median of $35000.0 in 2023.
- Biggest YoY gain for Change in Receivables was 777.14% in 2024; the steepest drop was 366.12% in 2024.
- A 4-year view of Change in Receivables shows it stood at -$664000.0 in 2023, then surged by 119.28% to $128000.0 in 2024, then surged by 82.03% to $233000.0 in 2025, then sank by 107.3% to -$17000.0 in 2026.
- The last three Change in Receivables figures came in at -$17000.0 (Q1 2026), $233000.0 (Q4 2025), and -$17000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -78.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 106.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -38.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 81.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 23.22 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 116.25 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.23 Mn |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | -17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | -809,000.00 |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Dec 31, 2023 | -664,000.00 |
| Dec 31, 2023 | -664,000.00 |